{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:55:06Z","timestamp":1782518106905,"version":"3.54.5"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/inf.0000000000001358","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T11:47:11Z","timestamp":1475840831000},"page":"87-93","source":"Crossref","is-referenced-by-count":23,"title":["A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule"],"prefix":"10.1097","volume":"36","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Arne","family":"Silfverdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Feroldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20-20210202","first-page":"337","article-title":"Revised guidance on the choice of pertussis vaccines: July 2014.","volume":"89","year":"2014","journal-title":"Releve epidemiologique hebdomadaire Section dhygiene du Secretariat de la Societe des Nations = Weekly epidemiological record Health Section of the Secretariat of the League of Nations"},{"key":"R3-20-20210202","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1542\/peds.2004-2759","article-title":"Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998\u20132001.","volume":"116","author":"Bisgard","year":"2005","journal-title":"Pediatrics"},{"key":"R4-20-20210202","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1016\/j.vaccine.2009.07.092","article-title":"Control of pertussis\u2013lessons learnt from a 10-year surveillance programme in Sweden.","volume":"27","author":"Carlsson","year":"2009","journal-title":"Vaccine"},{"key":"R5-20-20210202","first-page":"433","article-title":"Pertussis vaccines: WHO position paper - September 2015.","volume":"90","year":"2015","journal-title":"Releve epidemiologique hebdomadaire Section dhygiene du Secretariat de la Societe des Nations = Weekly epidemiological record Health Section of the Secretariat of the League of Nations"},{"key":"R6-20-20210202","first-page":"CD001478","article-title":"Acellular vaccines for preventing whooping cough in children.","volume":"9","author":"Zhang","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20-20210202","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/erv.11.72","article-title":"A DTaP-IPV\/\/PRP~T vaccine (Pentaxim): a review of 16 years\u2019 clinical experience.","volume":"10","author":"Plotkin","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"R8-20-20210202","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4161\/hv.4.5.6008","article-title":"Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations.","volume":"4","author":"Vidor","year":"2008","journal-title":"Hum Vaccin"},{"key":"R9-20-20210202","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1016\/j.vaccine.2010.02.049","article-title":"Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years.","volume":"28","author":"Tregnaghi","year":"2010","journal-title":"Vaccine"},{"key":"R10-20-20210202","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1016\/j.vaccine.2012.07.040","article-title":"A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.","volume":"30","author":"Aquino","year":"2012","journal-title":"Vaccine"},{"key":"R11-20-20210202","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.ijid.2010.12.004","article-title":"Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B\/\/PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.","volume":"15","author":"Kosalaraksa","year":"2011","journal-title":"Int J Infect Dis"},{"key":"R12-20-20210202","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/INF.0b013e318258400d","article-title":"Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America.","volume":"31","author":"Mac\u00edas","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20-20210202","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7196\/SAMJ.4401","article-title":"Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa.","volume":"101","author":"Madhi","year":"2011","journal-title":"S Afr Med J"},{"key":"R14-20-20210202","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/INF.0b013e318292f7b1","article-title":"Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles\/mumps\/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.","volume":"32","author":"Madhi","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20-20210202","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-013-0007-7","article-title":"DTaP-IPV-Hep B-Hib vaccine (Hexaxim\u00ae): a review of its use in primary and booster vaccination.","volume":"15","author":"McCormack","year":"2013","journal-title":"Paediatr Drugs"},{"key":"R16-20-20210202","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14712598.2013.774368","article-title":"Review of a new fully liquid, hexavalent vaccine: Hexaxim.","volume":"13","author":"Nunes","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"R17-20-20210202","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.vaccine.2012.11.087","article-title":"Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) following primary series administration at 2, 4, 6 months of age in Latin America.","volume":"31","author":"Santos-Lima","year":"2013","journal-title":"Vaccine"},{"key":"R18-20-20210202","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/INF.0b013e318242460a","article-title":"Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV\/\/PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV\/\/PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.","volume":"31","author":"Tregnaghi","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20-20210202","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1097\/INF.0b013e318212eb80","article-title":"Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants.","volume":"30","author":"Tregnaghi","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20-20210202","first-page":"19","article-title":"The European Medicine Agency\u2019s Article 58 Procedure: Reflections on the first approval for a vaccine.","volume":"10","author":"Paterson","year":"2013","journal-title":"Reguatory Rapporteur"},{"key":"R22-20-20210202","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40267-013-0078-0","article-title":"PL. DTaP-IPV-Hep B-Hib vaccine (Hexyon\u00ae\/Haxacima\u00ae): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe.","volume":"29","author":"Lyseng-Williamson","year":"2013","journal-title":"Drugs Therapy Perspect"},{"key":"R23-20-20210202","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00431-002-1079-5","article-title":"Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV\/Hib vaccine compared to separate concomitant injections of DTPa-IPV\/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.","volume":"161","author":"Avdicov\u00e1","year":"2002","journal-title":"Eur J Pediatr"},{"key":"R24-20-20210202","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00006454-199811000-00013","article-title":"Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.","volume":"17","author":"Carlsson","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20-20210202","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/00365540410017572","article-title":"Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age.","volume":"36","author":"Gabutti","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"R26-20-20210202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4161\/hv.5.1.6369","article-title":"Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age.","volume":"5","author":"Kilpi","year":"2009","journal-title":"Hum Vaccin"},{"key":"R27-20-20210202","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/CVI.00414-13","article-title":"Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV\/Hib vaccine administered at 3, 5, and 12 months of age.","volume":"20","author":"Vesikari","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"R30-20-20210202","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"R31-20-20210202","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"R32-20-20210202","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1473-3099(10)70195-X","article-title":"Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.","volume":"10","author":"Zanetti","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"R33-20-20210202","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.vaccine.2012.11.029","article-title":"Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level.","volume":"31","author":"Carollo","year":"2013","journal-title":"Vaccine"},{"key":"R34-20-20210202","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/eji.201041187","article-title":"Switched memory B cells maintain specific memory independently of serum antibodies: the hepatitis B example.","volume":"41","author":"Rosado","year":"2011","journal-title":"Eur J Immunol"},{"key":"R35-20-20210202","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1016\/j.vaccine.2012.06.078","article-title":"Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy.","volume":"30","author":"Zanetti","year":"2012","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:36Z","timestamp":1620954756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201701000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001358","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}